Cantargia Overview
- Year Founded
-
2009
- Status
-
Public
- Employees
-
23
- Stock Symbol
-
CANTA
- Investments
-
1
- Share Price
-
$0.13
- (As of Thursday Closing)
Cantargia General Information
Description
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.
Contact Information
Website
www.cantargia.comCorporate Office
- Scheelevägen 27
- 223 63 Lund
- Sweden
Corporate Office
- Scheelevägen 27
- 223 63 Lund
- Sweden
Cantargia Stock Performance
As of 19-Nov-2026, Cantargia’s stock price is $0.13. Its current market cap is $35.5M with 282M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.13 | $0.13 | $0.13 - $0.73 | $35.5M | 282M | 1.56M | $0.07 |
Cantargia Financials Summary
As of 30-Jun-2026, Cantargia has a trailing 12-month revenue of $33.9M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 28,351 | 76,346 | 22,770 | 48,667 |
| Revenue | 33,884 | 32,235 | 0 | 0 |
| EBITDA | 17,950 | 15,536 | (15,416) | (26,422) |
| Net Income | 17,874 | 14,960 | (15,285) | (26,345) |
| Total Assets | 31,666 | 32,239 | 15,446 | 22,385 |
| Total Debt | 0 | 0 | 0 | 0 |
Cantargia Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cantargia Patents
Cantargia Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024231251-A1 | Anti-il1rap antibodies | Inactive | 05-May-2023 | ||
| GB-202105933-D0 | Anti-il1rap antibody | Inactive | 26-Apr-2021 | ||
| CA-3202942-A1 | Anti-il1rap antibody | Pending | 23-Dec-2020 | ||
| WO-2022136569-A1 | Anti-il1rap antibody | Inactive | 23-Dec-2020 | ||
| EP-3837283-A1 | Anti-il1rap antibody compositions | Active | 16-Aug-2018 | C07K16/2866 |
Cantargia Signals
Cantargia Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Cantargia Investments (1)
Cantargia’s most recent deal was a Corporate Asset Purchase with Cellerant Therapeutics (Patent Portfolio of Interleukin 1 Receptor Accessory Protein). The deal was made on 10-Mar-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Cellerant Therapeutics (Patent Portfolio of Interleukin 1 Receptor Accessory Protein) | 10-Mar-2020 | Corporate Asset Purchase | Buildings and Property |
Cantargia ESG
Risk Overview
Risk Rating
Updated April, 30, 2023
35.07 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,766
Rank
Percentile
Pharmaceuticals
Industry
of 891
Rank
Percentile
Pharmaceuticals
Subindustry
of 435
Rank
Percentile
Cantargia FAQs
-
When was Cantargia founded?
Cantargia was founded in 2009.
-
Where is Cantargia headquartered?
Cantargia is headquartered in Lund, Sweden.
-
What is the size of Cantargia?
Cantargia has 23 total employees.
-
What industry is Cantargia in?
Cantargia’s primary industry is Drug Discovery.
-
Is Cantargia a private or public company?
Cantargia is a Public company.
-
What is Cantargia’s stock symbol?
The ticker symbol for Cantargia is CANTA.
-
What is the current stock price of Cantargia?
As of 19-Nov-2026 the stock price of Cantargia is $0.13.
-
What is the current market cap of Cantargia?
The current market capitalization of Cantargia is $35.5M.
-
What is Cantargia’s current revenue?
The trailing twelve month revenue for Cantargia is $33.9M.
-
What is Cantargia’s annual earnings per share (EPS)?
Cantargia’s EPS for 12 months was $0.07.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process